Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: DaVita is a leading provider of dialysis services in the United States. The company operates a network of dialysis centers and provides related services to patients with end-stage renal disease (ESRD). A significant portion of revenue is derived from government programs (Medicare/Medicaid) and commercial payors.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Net Operating Revenues | $676,820 | $1,935,825 |
| Operating Income | $112,338 | $328,649 |
| Net Income | $55,217 | $164,494 |
| Diluted Earnings Per Share (EPS) | $0.53 | $1.58 |
| Cash Provided by Operating Activities | N/A (Quarterly) | $302,210 |
| Cash and Cash Equivalents (Sep 30, 2005) | $337,196 | |
| Total Debt (Long-term + Current) | $1,365,014 | |
| Operating Margin (9 Months) | 17.0% |
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 13.6% year-over-year for the nine months ended September 30, 2005 ($1.94B vs. $1.68B). This was driven by a 12.5% increase in dialysis treatments (5.2% organic growth, 7.3% from acquisitions) and higher revenue per treatment.
- Profitability: Net income for the nine months decreased slightly to $164.5 million from $165.7 million in the prior year period. Operating income increased to $328.6 million from $305.0 million.
- Expense Increases: Patient care costs rose to $1.30 billion (9 months), driven by higher labor/benefit costs and hurricane impacts. General and administrative expenses increased to $174.9 million due to legal/compliance costs and integration expenses related to the pending Gambro Healthcare acquisition.
- Debt and Financing: Debt expense increased significantly to $66.7 million (9 months) from $36.6 million, reflecting higher interest rates and refinancing charges of $6.9 million associated with the repayment of prior term loans.
- Acquisitions: The company acquired 42 dialysis centers for $121.7 million during the first nine months of 2005.
Guidance, Outlook, and Risks
Outlook and Guidance
- Q4 2005: Management expects operating income to be comparable to Q3 2005, excluding additional integration costs.
- 2006 Projection: Operating income is projected in the range of $600 million to $670 million (pre-FASB 123R impact). This projection is subject to assessment of new CMS reimbursement proposals (composite rate add-on adjustment and EPO coverage policy).
- Integration Costs: Expected net integration costs for the Gambro Healthcare acquisition in the first year are estimated at $50 million, plus $25 million for IT equipment.
Material Events and Contingencies
- Gambro Healthcare Acquisition: On October 5, 2005, DaVita completed the acquisition of Gambro Healthcare for approximately $3.055 billion. This transaction significantly expands the company's footprint but introduces integration risks and contingent liabilities.
- Divestitures: To comply with an FTC consent order, DaVita divested 70 outpatient dialysis centers to Renal Advantage Inc. for approximately $328 million in cash consideration.
- Legal Proceedings: The company is subject to multiple subpoenas from U.S. Attorney's Offices (Missouri, New York, Pennsylvania) regarding billing practices, pharmaceutical relationships, and physician financial relationships. Potential outcomes include substantial penalties or exclusion from government programs.
- Regulatory Risks: Significant exposure to changes in Medicare reimbursement rates and policies regarding EPO and vitamin D analogs. Commercial payor rate pressure is also a noted risk.
Investor Verification Checklist
- Acquisition Integration: Verify the progress and cost of integrating Gambro Healthcare operations and the realization of anticipated synergies.
- Regulatory Investigations: Monitor the status of ongoing U.S. Attorney investigations and potential financial penalties or exclusion from Medicare/Medicaid.
- Reimbursement Policy Changes: Assess the impact of new CMS proposals on the 2006 composite rate and EPO coverage policies on future margins.
- Debt Service Capacity: Evaluate the company's ability to service its increased debt load (approx. $1.36B) given the high interest expense and integration costs.
- Commercial Payor Mix: Track the percentage of revenue from commercial payors versus Medicare, as commercial rates are under pressure and represent a significant margin driver.